3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
18
Leukemia
10
Leukemia, Myeloid, Chronic-Phase
7
Leukemia, Myeloid, Acute
7
Blast Crisis
7
Neoplasms
6
Leukemia, Myeloid, Accelerated Phase
6
Myeloproliferative Disorders
5
Carcinoma, Non-Small-Cell Lung
5
Neoplasms by Histologic Type
4
Leukemia, Myeloid
4
Hematologic Diseases
4
Bone Marrow Diseases
4
Myelodysplastic Syndromes
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Myelomonocytic, Chronic
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Neoplasms
2
Gastrointestinal Stromal Tumors
2
Gastrointestinal Neoplasms
2
Breast Neoplasms
2
Thyroid Neoplasms
1
Thrombocytosis
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Piebaldism
1
Interventions
Oxaliplatin
29
Fluorouracil
25
Leucovorin
20
Capecitabine
18
Irinotecan
17
Bevacizumab
14
Cisplatin
12
Surveys and Questionnaires
11
Gemcitabine
9
Drug Therapy
9
Standard of Care
8
Nivolumab
7
Cetuximab
7
pembrolizumab
6
S 1 (combination)
6
Cyclophosphamide
6
atezolizumab
5
Specimen Handling
5
Endoscopic Mucosal Resection
5
Educational Status
5
Docetaxel
5
Blood Specimen Collection
5
fludarabine
4
aldesleukin
4
Radiotherapy
4
Radiosurgery
4
Pemetrexed
4
IFL protocol
4
Folfox protocol
4
Everolimus
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Gastrointestinal Neoplasms
×
ponatinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled
NCT01874665
2018-05-18
GIST
Takeda
Phase 2
Completed
45 enrolled
21 charts